An interventional study of Contingency Management in Alcohol Use Disorder, Alcohol; Liver and Post Liver Transplant, sponsored by Arpan A. Patel, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Arpan A. Patel, MD · Not applicable, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,076 studies in Alcoholism with a site in United States — 190 open to participants now, 230 under way, 16 of them phase 3. Alcoholism · United States.
Among the 1,076 studies in Alcoholism with a site in United States, this one is the 899th largest by enrollment of the 992 interventional ones that give a count, is one of 59 that started in 2024, is one of 436 with no phase, and was the 929th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →190 of the 1,076 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 21–65
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 21–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,076 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 313 · Phase 3 78 · Phase 4 96
First in 1992; this study’s year is marked. 59 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 80 across the 992 interventional studies, 109 across the 79 observational. Of the 780 that completed or were terminated, 372 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 1,076 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Arpan A. Patel, MD as lead sponsor.
Arpan A. Patel, MD has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
83 of the studies in Alcoholism with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06173973Phase 3University of PennsylvaniaEffects of Ketone Supplementation on Acute Alcohol Withdrawal | 2026-12 |
| NCT05015881Phase 3University of PennsylvaniaRelationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder | 2026-12 |
| NCT04616781Phase 3University of PennsylvaniaKetone Ester Intervention in Alcohol Use Disorder | 2026-12 |
| NCT06702007Phase 3University of WashingtonElectronic Harm Reduction Treatment for Alcohol | 2027-01 |
| NCT05613608Phase 3University of Colorado, DenverAlcohol Use Disorder and Cannabidiol | 2027-04 |
Add all 83 to your calendar (.ics) → With an account.
Among the 1,076 studies in Alcoholism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD), the root cause of ALD, affects 15 million Americans each year. While research studies have shown that behavioral therapy and medications specific for alcohol use have helped people overcome their alcohol use disorder, there has not been enough information related to how successful these treatments are specifically for people with ALD. This study will look at a behavioral treatment called "contingency management" (CM) that has shown to be effective with people with other substance use disorders. CM is based on the principles of operant conditioning that involves offering prize-based or monetary incentives to patients with substance use disorders to reduce substance use. This study will look at the efficacy and acceptability of CM in patients who received a liver transplant and have evidence of recurrent alcohol use.
The proposed study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (TAU or control). Subjects will be asked to complete 12 study visits (including Screening and Baseline Visits) that will last 1 to 2 hours each depending on the visit. All visits will be completed via Zoom or by phone. Study staff will instruct participants on how to use Zoom, if necessary. During the Screening and Baseline Visits, subjects will be: 1) asked to provide a urine test and blood draw, 2) complete the SCID-5 AUD, a semi-structured interview guide for making the major DSM-5 diagnoses, 3) complete the Iowa Gambling Test which looks at decision-making skills, 4) complete a survey that looks at the subject's quality of life after liver transplant, 4) review how much alcohol the subject has consumed in the last 30 days, 5) and if the subject has received any current AUD treatments. Once the Screening and Baseline visits are completed, subjects will be randomized to either the CM group or the TAU group. During the weekly visits, subjects will be asked to provide blood and urine samples and will be asked if they have had any alcohol since their last visit. All subjects will receive $20 for completing the visits. For those in the CM group, subjects will also receive a CM reward for negative urine and/or blood tests, depending on which results we receive first-with rewards ranging from $5 to $80 depending on the week. Additionally, during weeks 1, 5, and 10, those in the CM group will also complete the Client Satisfaction Questionnaire-8 to assess client satisfaction with CM and complete a semi-structured interview about the CM protocol as well as CM acceptability and feasibility.
This study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (control).
Subjects will be recruited directly by research staff as well through MyChart messages.
For in-clinic subjects: Subjects will be identified by the RA via EMR review of patients listed for the day's clinic. Once identified, the Co-Investigator will approach the patient during the outpatient clinic visit with the recruitment flyer. The Co-Investigator will inform the participant that they may be eligible for the study. They will ask patients if the RA may contact them via phone to explain the study in more detail and/or answer any questions the subject may have after reviewing the flyer. If the subject agrees to be contacted, the Co-investigator will notify the RA and let the RA know that the subject has provided consent to contact. The RA will only contact the subject if the Co-Investigator has indicated the subject has provided permission to contact him or her. If the subject has declined permission for contact, the RA will not contact the subject, either by phone or other communication.
Alternatively, the RA may also approach potential subjects identified in clinic. The RA will provide the study flyer, explain the study in detail, and answer any questions the subject may have. If the subject voices interest in participating in the study, the RA can schedule the Consent and Baseline Visit that is mutually agreeable for the subject and RA. The RA will provide study contact information to the subject in case he or she needs to reschedule, or if any issues arise.
Identification by Clinical Staff: The PI will send quarterly emails to the clinical staff of the post-liver transplant clinics which includes physicians, nurse practitioners, social workers, and staff nurses. The email includes a brief summary of the study and the Eligibility Criteria. If the clinical staff have identified any potential subjects, they will email the PI or research assistant who will review the subject's electronic medical record to confirm eligibility. Once screened, the RA will send a MyChart message to the potential subject with study details and study contact information. If the subject is interested in the study and responds to the MyChart message through MyChart, by email, or by phone, then the RA will schedule the Consent and Baseline Visit according to the protocol.
MyChart Messages:
The study team will work with Care Connect analysts to create a work bench report that will identify patients that meet study criteria and the patients on the report will be sent a MyChart Recruitment message. The UCLA Embedded Clinical Research and Innovation (ECRI) team will run the workbench report and send out the messages. Only if the patient replies back with interest will the study team have access to their identifying information to contact them. The research assistant will review the subject's electronic medical record to confirm eligibility. Once screened, the RA will contact the potential subject via MyChart with more details about the study and to ask if they may contact them over the phone to discuss the study and answer any questions they may have. If they respond via MyChart that the RA may contact him or her, the RA will contact them via phone to explain the study, answer any questions, and if the subject is interested, schedule the Consent and Baseline Visit according to the protocol.
After written consent is obtained, the RA will confirm eligibility criteria:
If eligibility is confirmed and signed off by the PI, the participant will complete Baseline Visit activities via Zoom:
All participants will receive a $20 gift card for completing this visit, regardless of treatment arm.
After the initial visit, participants will attend weekly Zoom visits for 10 weeks and will complete assessments according to the protocol. At Visit 2, Visit 5, and Visit 10, participants will also undergo audio recorded semi-structured interviews about the CM protocol as well as CM acceptability and feasibility interviews with the research team. After these interviews, the audio-recordings will be analyzed as part of the study's first aim to look at the acceptability and feasibility of CM in the ALD population.
Since all weekly visits will be completed via Zoom or phone, participants will need to provide blood and urine samples at the nearest UCLA lab before their next weekly visit. CM rewards will not be provided until the study team receives the lab results for that week.
All participants will be compensated for completing each study visit with a gift card regardless of their randomization group. For those in the CM group, participants will also receive a CM reward for negative urine (EtG) and/or blood tests (PeTH), depending on which results are received first. Because PeTH can be elevated for several weeks after a positive test, a lower PeTH value in a subsequent week of checking will be considered a "negative" result, per previous studies. Additionally, if participants in the CM group have negative urine and/or blood test for 2 consecutive weeks, participants will receive a CM bonus.
The primary outcome for the study is the number of non-drinking days, which will be assessed by objective measures (i.e., presence of alcohol biomarkers in the blood and urine), as well as subjective measures (i.e., Timeline Followback). These assessments will be completed weekly. For the 10-week CM intervention, there will be a maximum of 70 non-drinking days.
Secondary outcomes include:
We will also obtain qualitative descriptions of acceptability and feasibility through individual, semi-structured interviews conducted with all 15 participants in the CM arm during three specific time points (V1, V5, V10).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Subjects randomized to treatment as usual (TAU) will not receive an intervention. They will continue with follow-up visits in the outpatient clinic as part of standard of care. .
Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
Behavioral: Contingency Management
Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
Number of Non-Drinking Days
The primary outcome for the study is the number of non-drinking days, which will be assessed by objective measures (i.e., presence of alcohol biomarkers in the blood and urine), as well as subjective measures (i.e., Timeline Followback). For the 10-week CM intervention, there will be a maximum of 70 non-drinking days.
Time frame: 10 Weeks
Patient-Reported Outcomes Measurement Information System (PROMIS® 29+2 Profile v2.1 (PROPr))
To assess health related quality of life. The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain.
Time frame: 10 Weeks
Client Satisfaction Questionnaire-8.
To assess acceptability of the CM program. An overall score is calculated by summing the respondent's rating (item rating) score for each scale item. For the CSQ-8 version, scores therefore range from 8 to 32, with higher values indicating higher satisfaction.
Time frame: 10 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in May 2026, 19 months.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's 19 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2026 → May 2026 and completion Sep 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.